Four Unique Genetic Variants in Three Genes Account for 62.7% of Early-Onset Severe Retinal Dystrophy in Chile: Diagnostic and Therapeutic Consequences
-
Published:2024-06-03
Issue:11
Volume:25
Page:6151
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Moya Rene1, Angée Clémentine2, Hanein Sylvain3ORCID, Jabot-Hanin Fabienne3, Kaplan Josseline2, Perrault Isabelle2ORCID, Rozet Jean-Michel2ORCID, Fares Taie Lucas2ORCID
Affiliation:
1. Department of Ophthalmology, Hospital del Salvador, Universidad de Chile, Santiago 7500922, Chile 2. Laboratory of Genetics in Ophthalmology (LGO), INSERM UMR1163, Institute of Genetic Diseases, Imagine and Paris Descartes University, 75015 Paris, France 3. Bioinformatic Platform, INSERM UMR1163, Institute of Genetic Diseases, Imagine and Paris Descartes University, 75015 Paris, France
Abstract
Leber congenital amaurosis (LCA)/early-onset severe retinal dystrophy (EOSRD) stand as primary causes of incurable childhood blindness. This study investigates the clinical and molecular architecture of syndromic and non-syndromic LCA/EOSRD within a Chilean cohort (67 patients/60 families). Leveraging panel sequencing, 95.5% detection was achieved, revealing 17 genes and 126 variants (32 unique). CRB1, LCA5, and RDH12 dominated (71.9%), with CRB1 being the most prevalent (43.8%). Notably, four unique variants (LCA5 p.Glu415*, CRB1 p.Ser1049Aspfs*40 and p.Cys948Tyr, RDH12 p.Leu99Ile) constituted 62.7% of all disease alleles, indicating their importance for targeted analysis in Chilean patients. This study underscores a high degree of inbreeding in Chilean families affected by pediatric retinal blindness, resulting in a limited mutation repertoire. Furthermore, it complements and reinforces earlier reports, indicating the involvement of ADAM9 and RP1 as uncommon causes of LCA/EOSRD. These data hold significant value for patient and family counseling, pharmaceutical industry endeavors in personalized medicine, and future enrolment in gene therapy-based treatments, particularly with ongoing trials (LCA5) or advancing preclinical developments (CRB1 and RDH12).
Funder
Institut National de la Santé et de la Recherche Médicale Association Retina France Foundation JED Belgique
Reference52 articles.
1. Inherited retinal diseases: Therapeutics, clinical trials and end points—A review;Georgiou;Clin. Exp. Ophthalmol.,2021 2. Leber congenital amaurosis/earlyonset severe retinal dystrophy: Clinical features, molecular genetics and therapeutic interventions;Kumaran;Br. J. Ophthalmol.,2017 3. Hasan, S.M., Azmeh, A., Mostafa, O., and Megarbane, A. (2016). Coat’s like vasculopathy in leber congenital amaurosis secondary to homozygous mutations in CRB1: A case report and discussion of the management options. BMC Res. Notes, 9. 4. Porto, F., Jones, E., Branch, J., Soens, Z., Maia, I., Sena, I., Sampaio, S., Simões, R., and Chen, R. (2017). Molecular Screening of 43 Brazilian Families Diagnosed with Leber Congenital Amaurosis or Early-Onset Severe Retinal Dystrophy. Genes, 8. 5. Ciliopathies: An expanding disease spectrum;Waters;Pediatr. Nephrol.,2011
|
|